Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines

zacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines Original Research (4912) Total Article Views Authors: Aaron N Nguyen, Paul W Hollenbach, Normand Richard, et al Published Date September 2010 Volume 2010:1(Default) Pages 119 - 140 DOI: http://dx.doi.org/10.2147/LCTT.S11726 Aaron N Nguyen1, Paul W Hollenbach1, Normand Richard2, Antonio Luna-Moran1, Helen Brady2, Carla Heise1, Kyle J MacBeth1 1Celgene Corporation, San Francisco, CA, USA; 2Celgene Corporation, San Diego, CA, USA Abstract: Azacitidine (AZA) and decitabine (DAC) are cytidine azanucleoside analogs with clinical activity in myelodysplastic syndromes (MDS) and potential activity in solid tumors. To better understand the mechanism of action of these drugs, we examined the effects of AZA and DAC in a panel of non-small cell lung cancer (NSCLC) cell lines. Of 5 NSCLC lines tested in a cell viability assay, all were sensitive to AZA (EC50 of 1.8–10.5 μM), while only H1299 cells were equally sensitive to DAC (EC50 of 5.1 μM). In the relatively DAC-insensitive cell line A549, both AZA and DAC caused DNA methyltransferase I depletion and DNA hypomethylation; however, only AZA significantly induced markers of DNA damage and apoptosis, suggesting that mechanisms in addition to, or other than, DNA hypomethylation are important for AZA-induced cell death. Cell cycle analysis indicated that AZA induced an accumulation of cells in sub-G1 phase, whereas DAC mainly caused an increase of cells in G2/M. Gene expression analysis of AZA- and DAC-treated cells revealed strikingly different profiles, with many genes distinctly regulated by each drug. In summary, while both AZA and DAC caused DNA hypomethylation, distinct effects were demonstrated on regulation of gene expression, cell cycle, DNA damage, and apoptosis.